


# High-Content Screening of GPCR activation Using MetaXpress and AcuityXpress Software and the Transflur Assay System

HIGH-CONTENT IMAGING SYSTEMS APPLICATION NOTE



By Susan Catalano, Ph.D., Acumen Pharmaceuticals, Sylvia de Bruin, Joe Bosworth, Ph.D., Neal Gliksman, Ph.D., Kimberly Best, Ph.D. and Paula Rickert, Ph.D., Molecular Devices, 1311 Orleans Drive, Sunnyvale, CA 94089.

## INTRODUCTION


G-protein coupled receptors (GPCRs) are the largest class of pharmaceutical targets and, as a result, assays for detecting GPCR receptor agonists and antagonists play a major role in screening operations. Recently Xsira Pharmaceuticals introduced the Transflur<sup>®</sup> Assay, a novel high-content assay that monitors GPCR activation by measuring GPCR desensitization and recycling. The Transflur Assay is now exclusively available from Molecular Devices.

The Transflur Assay, validated on over 90 different GPCRs, uses a common pathway independent of downstream G-protein signaling which is shared by virtually all GPCRs, representing all classes of GPCRs and G proteins. The assay uses image analysis to quantitate internalization of GFP-tagged beta-arrestin that associates with the receptor of interest following activation.<sup>1</sup> (See Figure 1.)

Unstimulated cells display diffuse cytoplasmic beta-arrestin-GFP fluorescence. When an over-expressed GPCR is activated, beta-arrestin targets the receptor for internalization, resulting in the appearance of small fluorescent clathrin-coated pits. If the receptor has a high affinity for beta-arrestin, the cells subsequently form fluorescent endocytic vesicles, which are larger and brighter

**Transflur Technology** (Figure 1)

Role of arrestins in model of GPCR desensitization and resensitization. (1) Agonist-activated GPCRs are phosphorylated by GRKs (G-protein coupled receptor kinases) on their carboxyl-terminal tails. (2) Arrestins (Arr) translocate to and bind the agonist-occupied, GRK-phosphorylated receptors at the plasma membrane. (3) Arrestins target the desensitized receptors to clathrin-coated pits for endocytosis. (4a) Some receptors bind arrestin with low affinity and dissociate from arrestin at or near the plasma membrane. (5) These receptors internalize without arrestin into endocytic vesicles and recycle rapidly. (4b) Other receptors bind arrestin with high affinity and remain associated with arrestin such that the receptor-arrestin complex internalizes as a unit into endocytic vesicles. (6) These receptors recycle slowly.




than pits. (See Figure 2.) The Transflour Assay has been widely adopted as both a primary and secondary screen in many pharmaceutical drug discovery operations as a functional measurement of physiological events downstream of GPCR activation.

MetaXpress® Imaging Software fully automates image acquisition and analysis of the Transflour Assay with all of Molecular Devices' high-content screening systems, including the ImageXpress® 5000A and Discovery-1™ Instruments. Optional application modules provide assay-specific turnkey analysis of common high-content assays. The Transflour module, described in this application note, was specifically designed and optimized for analyzing images from Transflour Assays.

MetaXpress Software is integrated with the enterprise-level MDCStore™ Database for managing images, cell-by-cell segmentation results and annotations. The AcuityXpress Cellular Informatics Platform is also seamlessly integrated with the MDCStore database, providing powerful data visualization and statistical tools for curve fitting, evaluating assay quality, and identifying hits, false positives, outliers and trends. Used together, MetaXpress and AcuityXpress Software and the Transflour Assay allow you to enhance your screening potential and rapidly discover GPCR modulators.

Practice of Transflour Assays requires a license available only through Molecular Devices. Contact your local sales representative for details on licensing and available Transflour Assay reagents.

**Transflour Assay Cellular Phenotypes** (Figure 2)



Activation of GPCRs in the Transflour Assay induces the formation of beta-arrestin-GFP-containing pits (A) or vesicles (B). Unstimulated cells show diffuse cytoplasmic distribution of beta-arrestin-GFP (C). Images were acquired at 20x on an ImageXpress 5000A Imaging System. Nuclei (blue) were stained with DAPI.

### MetaXpress Transflur Module (Figure 3)


#### CUSTOM CELL-BY-CELL ANALYSIS

MetaXpress Image Acquisition and Analysis Software optionally includes assay-specific application modules, designed for easy, interactive optimization of segmentation parameters. The simplified interface allows simple configuration and testing of analysis settings for your particular assay. (See Figure 3, Panel A.)

The MetaXpress Transflur Module uses the proprietary Adaptive Background Correction system to distinguish pits, vesicles and nuclei from their local surroundings so they can be selectively measured and counted, even in the presence of uneven staining or protein expression levels. This can be difficult to do using ordinary thresholding methods because the intensity of the pits can be marginally above background, and the GFP-tagged beta-arrestin expression levels can vary from cell to cell.

With the Transflur Module, designed for cell-by-cell analysis of Transflur data, pits and vesicles can be detected and distinguished simultaneously. The optional nuclear detection provides accurate counting of cells for data normalization. Three user-adjustable parameters are utilized for the image analysis. The “Approximate min width” and “Approximate max width” parameters are modified as needed for the expected size of the pits, vesicles or nuclei. The “Intensity above local background” parameter is adjusted for optimal discrimination of each pit or vesicle from the local background. This significantly improves the ability to identify and accurately quantitate actual pit and vesicle formation even if the intensity varies between cells in the image.

Multiple measurements can be logged to the database, including the number of pits or vesicles, total area covered by pits or vesicles, average and integrated intensity of the granules, and nuclear area and intensity. Results are provided on a cell-by-cell basis as well as summarized by image and site. Highlighting a row of the cellular results table immediately highlights the corresponding cell and overlay in the image. (See Figure 3, Panels B and C.)



MetaXpress Software application modules allow users to set various parameters interactively. A) Configure Settings dialog for the Transflur module, B) Cell-by-cell results, C) Highlighted cell corresponding to selection in panel B.

## MATERIALS

Practice of Transfluo Assays requires a license from Molecular Devices. Transfluo Assay reagents are available to Transfluo licensees from Molecular Devices. Contact Molecular Devices for details.

*Note: All solutions should be freshly prepared immediately before each experiment.*

- Beta-arrestin-GFP and Beta-2-adrenergic receptor ( $\beta$ 2AR)-expressing U2OS cells (Molecular Devices)
- Corning Costar 384-well microplates (Cat. #3712)
- U2OS media: MEM (Gibco Cat. #11095) with 10% heat-inactivated FCS (Gibco Cat. #10082), 10  $\mu$ g/mL gentamicin (Gibco Cat. #15710), 10 mM HEPES (Gibco Cat. #11344), 0.4 mg/mL Zeocin (Gibco Cat. #R250) and 0.4 mg/mL G418 (Gibco Cat. #10131)
- Ascorbic acid media: 5.7 mM solution of ascorbic acid (sodium L-ascorbate, SIGMA Cat. #A7631) in serum- and antibiotic-free media (MEM with 10 mM HEPES)
- Isoproterenol stock solution: 175  $\mu$ M stock solution of (-)-isoproterenol (+)-bitartrate salt (SIGMA Cat. #I2760) in ascorbic acid media
- Propranolol stock solution: 125  $\mu$ M solution of (s)-(-)-propranolol hydrochloride (SIGMA Cat. #P8688) in serum- and antibiotic-free media (MEM with 10 mM HEPES)
- DPBS (SIGMA Cat. #D8537)
- 4% methanol-free formaldehyde: 16% methanol-free formaldehyde (Polysciences Cat. #18814) diluted 1:4 in DPBS
- DAPI, dilactate (Molecular Probes D-3571)

## METHODS

### Agonist dose-response assay

Step 1. Plate cells at 4,500 cells/well in 25  $\mu$ L of U2OS media. Incubate overnight at 37°C, 5% CO<sub>2</sub>.

Step 2. Perform 10 five-fold serial dilutions of the isoproterenol stock solution in the ascorbic acid media to form an 11-point series of 3.5X isoproterenol dose-response solutions. Use ascorbic acid media alone as a negative control. (See Table 1.)

3.5X Concentration	Final Concentration
175 $\mu$ M	50 $\mu$ M
35 $\mu$ M	10 $\mu$ M
7 $\mu$ M	2 $\mu$ M
1.4 $\mu$ M	400 nM
280 nM	80 nM
56 nM	16 nM
11.2 nM	3.2 nM
2.2 nM	640 pM
448 pM	128 pM
89.6 pM	25.6 pM
17.9 pM	5.1 pM
0 $\mu$ M	0 $\mu$ M

Step 3. Add 10  $\mu$ L of the appropriate 3.5X isoproterenol dose-response solution or negative control to each well.

Step 4. Incubate at 37°C, 5% CO<sub>2</sub> for 40–45 minutes (vesicle formers) or 30 minutes (pit formers).

### Antagonist dose-inhibition assay

Step 1. Plate cells at 4,500 cells/well in 23  $\mu$ L of U2OS media. Incubate overnight at 37°C, 5% CO<sub>2</sub>.

Step 2. Prepare a 175 nM 3.5X isoproterenol stimulation solution by diluting the 175  $\mu$ M isoproterenol stock 1:1000 in the ascorbic acid media.

Step 3. Perform ten five-fold serial dilutions of the propranolol stock solution in MEM with

Hepes to form a series of 12.5X propranolol dose-inhibition solutions. Use MEM/Hepes alone as a negative control. (See Table 2.)

12.5X Concentration	Final Concentration
125 $\mu$ M	10 $\mu$ M
25 $\mu$ M	2 $\mu$ M
5 $\mu$ M	400 nM
1 $\mu$ M	80 nM
200 nM	16 nM
40 nM	3.2 nM
8 nM	640 pM
1.6 nM	128 pM
320 pM	25.6 pM
64 pM	5.1 pM
12.8 pM	1.0 pM
0 $\mu$ M	0 $\mu$ M

Step 4. Add 2  $\mu$ L of the appropriate 12.5X propranolol dose-inhibition solution or negative control to each well.

Step 5. Incubate at 37°C, 5% CO<sub>2</sub> for 30 minutes.

Step 6. Add 10  $\mu$ L of the 175 nM isoproterenol stimulation solution or ascorbic acid media (unstimulated control) to each well.

Step 7. Incubate at 37°C, 5% CO<sub>2</sub> for 40–45 minutes (vesicle formers) or 30 minutes (pit formers).

### Sample fixing and staining

Step 1. Stop assay by adding 35  $\mu$ L 4% methanol-free formaldehyde to each well. Cover and incubate for 45 minutes at room temperature.

Step 2. Wash each well with 50  $\mu$ L DPBS.

Step 3. Add 8  $\mu$ L of 0.05 mg/mL DAPI to each well. Incubate at room temperature for 15 minutes.

Step 4. Rinse wells twice with 75  $\mu$ L DPBS, leaving in 75  $\mu$ L DPBS.

Step 5. Cover plate with a plate seal and store at 4°C, protected from light, until image acquisition.

**Image acquisition**

Step 1. Using MetaXpress Software, acquire unbinned images on an ImageXpress 5000A or Discovery-1 imaging system using DAPI and FITC filter sets and a 20x Plan Fluor or Plan Fluor ELWD objective. The results described here were obtained from imaging two sites per well.

**Image analysis**

Step 1. In MetaXpress Software, retrieve your images of interest from the database and analyze them with the Transfluo Assay Application Module. Select the appropriate source images, minimum and maximum widths, and intensity above local background for both the pit/vesicle staining and the nuclear staining.


Step 2. In AcuityXpress Software, annotate your plates with the appropriate compounds and concentrations.

Step 3. Create a dataset containing your plates of interest and perform curve fitting to obtain  $EC_{50}$  and  $IC_{50}$  values for each compound.


**ASSAY RESULTS**

U2OS cells expressing beta-arrestin-GFP and either wild-type  $\beta 2AR$  (pit formers) or enhanced  $\beta 2AR$  (vesicle formers) were treated with either isoproterenol (agonist) or propranolol (antagonist). The enhanced  $\beta 2AR$  has a modified C-terminal tail to increase its affinity for beta-arrestin, resulting in fluorescent vesicle formation.

Images were acquired on an ImageXpress 5000A System as described above, and analyzed with the Transfluo Assay Application Module. Similar results were obtained on a Discovery-1 System (data not shown). The accuracy of the module is illustrated in Figure 4 (pit phenotype) and Figure 5 (vesicle phenotype). The images show that the algorithm properly identifies pits and vesicles in either phenotype for cells stimulated with varying concentrations of the agonist isoproterenol. Unstimulated cells display minimal pits or vesicles.

**Agonist Stimulation of Pit Formation (Figure 4)**

Analyzed images of dose-dependent beta-arrestin-GFP translocation upon activation of WT $\beta 2AR$ . Cells were treated with 0 nM (A), 3.2 nM (B), 400 nM (C), or 50  $\mu M$  (D) isoproterenol. The Transfluo Assay Application Module accurately identified pit formation induced by agonist stimulation.

**Agonist Inhibition of Vesicle Formation (Figure 5)**

Analyzed images of dose-dependent inhibition of arrestin-GFP translocation caused by stimulation of a tail-modified  $\beta 2AR$ . Cells were treated with 0 nM (A), 0.6 nM (B), 80 nM (C), or 10  $\mu M$  (D) propranolol and stimulated with 50 nM isoproterenol. The Transfluo Assay Application Module accurately identified vesicle formation blocked by antagonist inhibition.

**DOSE-RESPONSE AND DOSE-INHIBITION ANALYSIS**

In both pit- and vesicle-forming cell lines, the dose-response of the agonist isoproterenol and the dose-inhibition of the antagonist propranolol were measured with the MetaXpress Software Transfluor Application Module. Each dose was run across six replicate wells. Figure 6 shows a plate heat map generated by AcuityXpress Software, demonstrating the dose-dependent response of the assay.

For EC<sub>50</sub> and IC<sub>50</sub> calculations, Hill curve fitting was performed on pit or vesicle area per cell, averaged across all replicate wells on the plate, plotted against compound concentration. AcuityXpress automatically generates curve fits for your entire dataset, encompassing multiple compounds and multiple plates, if appropriate. (See Figure 7.) Table 3 provides a summary of the agonist EC<sub>50</sub> and antagonist IC<sub>50</sub> for both cell lines from two independent experiments. These values correspond well to reports in the literature<sup>2</sup> of isoproterenol stimulation of the beta-2-adrenergic receptor with an EC<sub>50</sub> of 1–10 nM and propranolol antagonism with an IC<sub>50</sub> = 0.5–5 nM.


Table 3. Measured EC <sub>50</sub> and IC <sub>50</sub> Values for Beta-2-Adrenergic Receptor Stimulation and Inhibition		
	Isoproterenol EC <sub>50</sub> (nM)	Propranolol IC <sub>50</sub> (nM)
<b>Pit Phenotype</b>		
Experiment 1	4.7	4.3
Experiment 2	8.1	4.3
<b>Vesicle Phenotype</b>		
Experiment 1	3.4	3.7
Experiment 2	6.3	3.7

**Plate Heat Map (Figure 6)**



The Plate tab in AcuityXpress shows a heat map of any measurement in plate layout, allowing a quick view of trends across a plate. Here total vesicle count per well is shown, with 3 different assays performed on the same plate. An agonist (isoproterenol) dose-response assay was run in C03-N08. A control antagonist dose-inhibition without stimulation was run in C10-N15. An antagonist (propranolol) dose-inhibition of isoproterenol stimulation was run in C17-N22.

**Agonist Dose-Response and Antagonist Dose-Inhibition Curves (Figure 7)**



Quantification of beta-arrestin-GFP translocation to β2AR in a pit-forming (A, B) and a vesicle-forming (C, D) cell line. Dose-response (A, C) curves were generated by treatment with various concentrations of the agonist isoproterenol. Dose-inhibition (B, D) curves were generated by pre-treatment with various concentrations of the antagonist propranolol followed by stimulation with isoproterenol. Data shown are the means ± SD from six wells per concentration. Each curve represents an independent experiment.

#### ASSAY STATISTICAL SUMMARY

The Z' factors (see Table 4) were calculated for both experiments.<sup>3</sup> The Z' factor, a measure of assay quality, reflects both the data variation and the signal dynamic range. The Z' factors measured for this experiment are > 0.6, easily within the desirable range for a cell-based imaging assay.

<b>Table 4. Z' Statistical Summary for Agonist Stimulation and Antagonist Inhibition</b>		
	<b>Agonist Dose-Response Z'</b>	<b>Agonist Dose-Inhibition Z'</b>
<b>Pit Phenotype</b>		
<b>Experiment 1</b>	0.8	0.9
<b>Experiment 2</b>	0.9	0.8
<b>Vesicle Phenotype</b>		
<b>Experiment 1</b>	0.8	0.8
<b>Experiment 2</b>	0.7	0.9

#### DISCUSSION

The MetaXpress Software Transflour Application Module successfully identifies cells and measures pits and vesicles formed by beta-arrestin-GFP translocation to activated GPCRs in the Transflour Assay. Independent experiments with the beta-2-adrenergic receptor, both wild-type and enhanced, produce consistent EC<sub>50</sub> and IC<sub>50</sub> values with high Z' factors. These results demonstrate that the Transflour Assay as analyzed by MetaXpress Software is a highly robust and reproducible assay for GPCR activation.

The rapid acquisition, analysis and data visualization capabilities of MetaXpress and AcuityXpress Software combined with the universality of the Transflour Assay offer a uniquely powerful approach for screening GPCR modulators.

#### REFERENCES

1. Oakley, R.H., Hudson, C.C., Cruickshank, R.D., Meyers, D.M., Payne, R.E. Jr., Rhem, S.M., Loomis, C.R. The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G-protein-coupled receptors. *Assay Drug Devel Tech* 2003;1:21–30.
2. Oakley, R.H., Laporte, S.A., Holt, J.A., Barak, L.S., Caron, M.G. Association of beta-arrestin with G-protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. *J Biol Chem* 1999;274:32248–32257.
3. Zhang, J.H., Chung, T.D., Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J Biomol Screen* 1999;4:67–73.

**SALES OFFICES***United States & Canada*

Molecular Devices  
Tel. +1-800-635-5577  
Fax +1-408-747-3601

*Brazil*

Molecular Devices Brazil  
Tel. +55-11-3616-6607  
Fax +55-11-3616-6607

*China*

Molecular Devices Beijing  
Tel. +86-10-6410-8669  
Fax +86-10-6410-8601

*Molecular Devices Shanghai*

Tel. +86-21-6887-8820  
Fax +86-21-6887-8890

*Germany*

Molecular Devices GmbH  
Tel. +49-89/96-05-88-0  
Fax +49-89/9-62-02-34-5

*Japan*

Molecular Devices Japan, Osaka  
Tel. +81-6-6399-8211  
Fax +81-6-6399-8212

*Molecular Devices Japan, Tokyo*

Tel. +81-3-5282-5261  
Fax +81-3-5282-5262

*South Korea*

Molecular Devices Korea, LLC  
Tel. +82-2-3471-9531  
Fax +82-2-3471-9532

*United Kingdom*

Molecular Devices Ltd.  
Tel. +44-118-944-8000  
Fax +44-118-944-8001

[www.moleculardevices.com](http://www.moleculardevices.com)

FOR RESEARCH USE ONLY. NOT FOR USE IN  
DIAGNOSTIC PROCEDURES.

The trademarks used herein are the property  
of Molecular Devices, LLC or their respective  
owners.

Specifications subject to change without notice.

©2010 Molecular Devices, LLC. Printed in U.S.A.  
6/10 #0120-1391.C2

Patents: <http://www.moleculardevices.com/productpatents>